Market Cap 13.97B
Revenue (ttm) 8.25B
Net Income (ttm) 478.00M
EPS (ttm) N/A
PE Ratio 13.60
Forward PE 13.39
Profit Margin 5.79%
Debt to Equity Ratio 1.03
Volume 398,000
Avg Vol 1,078,272
Day's Range N/A - N/A
Shares Out 173.45M
Stochastic %K 10%
Beta 0.26
Analysts Sell
Price Target $88.27

Company Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 651 733 1110
Address:
3M Center, Building 275-6W-20 2510 Conway Avenue East St. Paul, Maplewood, United States
ZacksResearch
ZacksResearch Dec. 24 at 8:01 PM
$SOLV makes a bold move in advanced wound care — this one matters. Solventum is buying Acera Surgical for $725M upfront, entering the tissue matrices space and expanding its MedSurg and wound care portfolio — a clear strategic push into higher-value solutions. 🧠 See what this acquisition means for the business 👉 https://www.zacks.com/stock/news/2808854/solv-acquires-acera-surgical-to-expand-advanced-wound-care-portfolio?cid=sm-stocktwits-2-2808854-teaser-26335&ADID=SYND_STOCKTWITS_TWEET_2_2808854_TEASER_26335
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 7:01 PM
$SOLV acquisition alert! 🏥💼 Solventum's $725M deal for Acera Surgical, with an additional $125M contingent payment, positions them in the fast-growing synthetic tissue matrices market. This move strengthens their MedSurg business and aligns with their transformation plan. Shares dipped 0.3% post-announcement, but SOLV's 7.4% gain over six months outpaces the industry's 2.3% growth — a noteworthy development. Discover the full strategic impact here 👉 https://www.zacks.com/stock/news/2808854/solv-acquires-acera-surgical-to-expand-advanced-wound-care-portfolio?cid=sm-stocktwits-2-2808854-body-26336&ADID=SYND_STOCKTWITS_TWEET_2_2808854_BODY_26336
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 3:40 PM
$SOLV RSI: 32.89, MACD: 0.6526 Vol: 2.17, MA20: 82.72, MA50: 77.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CodeSurge
CodeSurge Dec. 22 at 2:36 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:14 PM
Actionable Trade Alert for $SOLV: Market Context: $SOLV is currently trading at $80.68, near its 30-day moving average of $80.04 and significantly above its 60-day low of $66.11. The RSI of 32.11 indicates that the asset is oversold, suggesting potential upward momentum. Directional Bias: Given the oversold RSI and proximity to the MA30, there is a bullish bias. The price is also below the 60-day high of $88.2, indicating room for growth. Trade Plan: - Suggested Entry: $80.68 - Stop Loss: $78.00 (below recent support) - Take Profit Targets: 1. TP1: $84.00 (5.8% ROI) 2. TP2: $88.00 (9.0% ROI) 3. TP3: $94.00 (16.5% ROI) With a risk-reward ratio favoring the upside, this trade presents a solid opportunity for a significant return. Monitor closely for any changes in market sentiment or technical indicators. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:01 AM
$SOLV Actionable Trade Alert: Market Context: $SOLV is currently trading at $80.59, with a recent RSI of 28.31 indicating it is oversold. This suggests a potential reversal or upward movement. The price is above the 30-day moving average (MA30) of $79.23 and significantly above the 50-day moving average (MA50) of $76.05, indicating a bullish bias in the short term. Directional Bias: The current price is near the 60-day low of $66.11, providing a strong support level. The oversold RSI and proximity to support suggest a potential bounce back. Trade Plan: - Suggested Entry: $80.59 - Stop Loss: $78.00 (around 3.2% below entry) - Take Profit Targets: 1. Target 1: $84.00 (4.8% gain) 2. Target 2: $88.00 (9.1% gain) 3. Target 3: $94.50 (17.3% gain) This plan offers a favorable risk-reward ratio with a potential 17% ROI on the third target. Monitor closely for market movements. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:34 AM
$SOLV Actionable Trade Alert: Market Context: $SOLV is currently trading at $82.98, showing a neutral RSI of 50.32, which indicates no strong momentum in either direction. However, the price is above both the 30-day MA of 78.39 and the 50-day MA of 75.76, suggesting a bullish bias in the short to medium term. Directional Bias: The proximity to the 60-day high of 88.2 implies potential upward movement, while the 60-day low of 66.11 provides a solid support level. The ATR of 1.85 indicates moderate volatility, allowing for reasonable price movements. Trade Plan: - Suggested Entry: $83.50 - Stop Loss: $80.00 (3.02% risk) - Take Profit Targets: 1. TP1: $86.00 (2.98% gain) 2. TP2: $89.00 (6.75% gain) 3. TP3: $97.00 (17.00% gain) This plan aims for a minimum of 17% ROI on TP3, aligning with the current market metrics. https://privateprofiteers.com
0 · Reply
bigbulldaddy
bigbulldaddy Dec. 13 at 2:05 PM
$SOLV We bought ascera which is cool. Growth potential here. The restructure recently is a very interesting choice. They eliminated a key associate rep role that is responsible for managing the home rental VAC business through case managers. It also helped hospitals not lose expensive rental VAC units (which happens frequently). The clinical role was also eliminated which is another interesting choice with the product being difficult to use at times and needing clinical expertise. SOLV will definitely save money in sales expenditures but it really isn’t clear if this is a good idea. Their acute and post acute roles will have to pick up the slack for the missing roles. There will be balls dropped. Some of those balls will have consequences. They think they helped by making territories slightly smaller but it isn’t significantly different. I’m forecasting a hard Q1 while they try to bounce back from the restructure. Ascera restructure still coming…
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:28 PM
$SOLV is currently positioned at $82.17, showing a strong momentum with an RSI of 58.86, indicating bullish sentiment but not overbought. The price is above the 30-day moving average (MA30) of $77.91 and the 50-day moving average (MA50) of $75.58, suggesting a positive trend. The 60-day high of $88.2 provides a clear resistance level, while the 60-day low of $66.11 offers support. Actionable Trade Alert: - Suggested Entry: $82.50 - Stop Loss: $79.00 (3.04% below entry) - Take Profit Targets: 1. $85.00 (3.03% gain) 2. $87.00 (5.97% gain) 3. $96.00 (16.5% gain) The trade plan capitalizes on the upward momentum and proximity to the recent high, with a favorable risk-reward ratio. The stop loss protects against significant downturns while allowing for substantial upside potential. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:31 AM
Actionable Trade Alert for $SOLV: Market Context: The last close for $SOLV is $80.11, with a bullish sentiment indicated by an RSI of 60.35, suggesting momentum is building. The price is above both the 30-day moving average (MA30) of $77.13 and the 50-day moving average (MA50) of $75.22, indicating a strong upward trend. Directional Bias: With the current price near the 60-day high of $88.2, there is potential for further gains. The RSI indicates that the stock is not yet overbought, allowing room for upward movement. Trade Plan: - Suggested Entry: $80.50 - Stop Loss: $77.00 (3.1% below entry) - Take Profit Targets: 1. $84.00 (4.6% gain) 2. $88.00 (9.3% gain) 3. $94.00 (17.1% gain) With this plan, we aim for a minimum of 17% ROI on the third target while maintaining a manageable risk. https://privateprofiteers.com
0 · Reply
Latest News on SOLV
Solventum Completes Acquisition of Acera Surgical

Dec 23, 2025, 4:05 PM EST - 1 day ago

Solventum Completes Acquisition of Acera Surgical


Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not

Dec 11, 2025, 10:17 PM EST - 13 days ago

Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not


Solventum Announces $1 Billion Share Repurchase Program

Nov 20, 2025, 9:00 AM EST - 4 weeks ago

Solventum Announces $1 Billion Share Repurchase Program


Solventum Announces Agreement to Acquire Acera Surgical

Nov 20, 2025, 9:00 AM EST - 4 weeks ago

Solventum Announces Agreement to Acquire Acera Surgical


Solventum Corporation (SOLV) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:26 PM EST - 6 weeks ago

Solventum Corporation (SOLV) Q3 2025 Earnings Call Transcript


Solventum Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 6 weeks ago

Solventum Reports Third Quarter 2025 Financial Results


Solventum: A Solid Performance Here

Oct 22, 2025, 12:42 PM EDT - 2 months ago

Solventum: A Solid Performance Here


Solventum Appoints Heather Knight as Chief Commercial Officer

Oct 21, 2025, 5:00 PM EDT - 2 months ago

Solventum Appoints Heather Knight as Chief Commercial Officer


Solventum to Participate in Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 4 months ago

Solventum to Participate in Upcoming Investor Conferences


Solventum Announces $1.75 Billion Note Tender Offers

Aug 22, 2025, 8:19 AM EDT - 4 months ago

Solventum Announces $1.75 Billion Note Tender Offers


Solventum Announces Pricing of Secondary Offering of Common Stock

Aug 13, 2025, 10:39 PM EDT - 4 months ago

Solventum Announces Pricing of Secondary Offering of Common Stock


Solventum Announces Launch of Secondary Offering of Common Stock

Aug 13, 2025, 4:48 PM EDT - 4 months ago

Solventum Announces Launch of Secondary Offering of Common Stock


Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 6:53 AM EDT - 4 months ago

Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript


Solventum Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Solventum Reports Second Quarter 2025 Financial Results


Solventum: Appealing Again

Jul 22, 2025, 9:12 AM EDT - 5 months ago

Solventum: Appealing Again


Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript

May 11, 2025, 5:07 PM EDT - 8 months ago

Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript


Solventum Corporation: Cheap, With Caveats

May 9, 2025, 11:02 AM EDT - 8 months ago

Solventum Corporation: Cheap, With Caveats


Solventum Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 8 months ago

Solventum Reports First Quarter 2025 Financial Results


Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 8:36 AM EST - 10 months ago

Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript


Solventum In The Early Stages Of A Multiyear Turnaround Effort

Feb 25, 2025, 10:16 AM EST - 10 months ago

Solventum In The Early Stages Of A Multiyear Turnaround Effort


ZacksResearch
ZacksResearch Dec. 24 at 8:01 PM
$SOLV makes a bold move in advanced wound care — this one matters. Solventum is buying Acera Surgical for $725M upfront, entering the tissue matrices space and expanding its MedSurg and wound care portfolio — a clear strategic push into higher-value solutions. 🧠 See what this acquisition means for the business 👉 https://www.zacks.com/stock/news/2808854/solv-acquires-acera-surgical-to-expand-advanced-wound-care-portfolio?cid=sm-stocktwits-2-2808854-teaser-26335&ADID=SYND_STOCKTWITS_TWEET_2_2808854_TEASER_26335
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 7:01 PM
$SOLV acquisition alert! 🏥💼 Solventum's $725M deal for Acera Surgical, with an additional $125M contingent payment, positions them in the fast-growing synthetic tissue matrices market. This move strengthens their MedSurg business and aligns with their transformation plan. Shares dipped 0.3% post-announcement, but SOLV's 7.4% gain over six months outpaces the industry's 2.3% growth — a noteworthy development. Discover the full strategic impact here 👉 https://www.zacks.com/stock/news/2808854/solv-acquires-acera-surgical-to-expand-advanced-wound-care-portfolio?cid=sm-stocktwits-2-2808854-body-26336&ADID=SYND_STOCKTWITS_TWEET_2_2808854_BODY_26336
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 3:40 PM
$SOLV RSI: 32.89, MACD: 0.6526 Vol: 2.17, MA20: 82.72, MA50: 77.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CodeSurge
CodeSurge Dec. 22 at 2:36 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:14 PM
Actionable Trade Alert for $SOLV: Market Context: $SOLV is currently trading at $80.68, near its 30-day moving average of $80.04 and significantly above its 60-day low of $66.11. The RSI of 32.11 indicates that the asset is oversold, suggesting potential upward momentum. Directional Bias: Given the oversold RSI and proximity to the MA30, there is a bullish bias. The price is also below the 60-day high of $88.2, indicating room for growth. Trade Plan: - Suggested Entry: $80.68 - Stop Loss: $78.00 (below recent support) - Take Profit Targets: 1. TP1: $84.00 (5.8% ROI) 2. TP2: $88.00 (9.0% ROI) 3. TP3: $94.00 (16.5% ROI) With a risk-reward ratio favoring the upside, this trade presents a solid opportunity for a significant return. Monitor closely for any changes in market sentiment or technical indicators. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:01 AM
$SOLV Actionable Trade Alert: Market Context: $SOLV is currently trading at $80.59, with a recent RSI of 28.31 indicating it is oversold. This suggests a potential reversal or upward movement. The price is above the 30-day moving average (MA30) of $79.23 and significantly above the 50-day moving average (MA50) of $76.05, indicating a bullish bias in the short term. Directional Bias: The current price is near the 60-day low of $66.11, providing a strong support level. The oversold RSI and proximity to support suggest a potential bounce back. Trade Plan: - Suggested Entry: $80.59 - Stop Loss: $78.00 (around 3.2% below entry) - Take Profit Targets: 1. Target 1: $84.00 (4.8% gain) 2. Target 2: $88.00 (9.1% gain) 3. Target 3: $94.50 (17.3% gain) This plan offers a favorable risk-reward ratio with a potential 17% ROI on the third target. Monitor closely for market movements. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:34 AM
$SOLV Actionable Trade Alert: Market Context: $SOLV is currently trading at $82.98, showing a neutral RSI of 50.32, which indicates no strong momentum in either direction. However, the price is above both the 30-day MA of 78.39 and the 50-day MA of 75.76, suggesting a bullish bias in the short to medium term. Directional Bias: The proximity to the 60-day high of 88.2 implies potential upward movement, while the 60-day low of 66.11 provides a solid support level. The ATR of 1.85 indicates moderate volatility, allowing for reasonable price movements. Trade Plan: - Suggested Entry: $83.50 - Stop Loss: $80.00 (3.02% risk) - Take Profit Targets: 1. TP1: $86.00 (2.98% gain) 2. TP2: $89.00 (6.75% gain) 3. TP3: $97.00 (17.00% gain) This plan aims for a minimum of 17% ROI on TP3, aligning with the current market metrics. https://privateprofiteers.com
0 · Reply
bigbulldaddy
bigbulldaddy Dec. 13 at 2:05 PM
$SOLV We bought ascera which is cool. Growth potential here. The restructure recently is a very interesting choice. They eliminated a key associate rep role that is responsible for managing the home rental VAC business through case managers. It also helped hospitals not lose expensive rental VAC units (which happens frequently). The clinical role was also eliminated which is another interesting choice with the product being difficult to use at times and needing clinical expertise. SOLV will definitely save money in sales expenditures but it really isn’t clear if this is a good idea. Their acute and post acute roles will have to pick up the slack for the missing roles. There will be balls dropped. Some of those balls will have consequences. They think they helped by making territories slightly smaller but it isn’t significantly different. I’m forecasting a hard Q1 while they try to bounce back from the restructure. Ascera restructure still coming…
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:28 PM
$SOLV is currently positioned at $82.17, showing a strong momentum with an RSI of 58.86, indicating bullish sentiment but not overbought. The price is above the 30-day moving average (MA30) of $77.91 and the 50-day moving average (MA50) of $75.58, suggesting a positive trend. The 60-day high of $88.2 provides a clear resistance level, while the 60-day low of $66.11 offers support. Actionable Trade Alert: - Suggested Entry: $82.50 - Stop Loss: $79.00 (3.04% below entry) - Take Profit Targets: 1. $85.00 (3.03% gain) 2. $87.00 (5.97% gain) 3. $96.00 (16.5% gain) The trade plan capitalizes on the upward momentum and proximity to the recent high, with a favorable risk-reward ratio. The stop loss protects against significant downturns while allowing for substantial upside potential. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:31 AM
Actionable Trade Alert for $SOLV: Market Context: The last close for $SOLV is $80.11, with a bullish sentiment indicated by an RSI of 60.35, suggesting momentum is building. The price is above both the 30-day moving average (MA30) of $77.13 and the 50-day moving average (MA50) of $75.22, indicating a strong upward trend. Directional Bias: With the current price near the 60-day high of $88.2, there is potential for further gains. The RSI indicates that the stock is not yet overbought, allowing room for upward movement. Trade Plan: - Suggested Entry: $80.50 - Stop Loss: $77.00 (3.1% below entry) - Take Profit Targets: 1. $84.00 (4.6% gain) 2. $88.00 (9.3% gain) 3. $94.00 (17.1% gain) With this plan, we aim for a minimum of 17% ROI on the third target while maintaining a manageable risk. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:20 PM
Actionable Trade Alert for $SOLV: Market Context: $SOLV is currently experiencing bullish momentum, indicated by its last close at $84.05 and an RSI of 81.9, suggesting it is overbought. However, the price is above both the 30-day MA (76.91) and the 50-day MA (75.09), indicating strong upward momentum. Directional Bias: The bullish trend is reinforced by the recent high of $88.2, which is within reach. The RSI indicates potential overextension, but a pullback could provide a buying opportunity. Trade Plan: - Suggested Entry: $84.05 - Stop Loss: $81.00 (3.65% below entry) - Take Profit Targets: 1. $87.00 (3.48% gain) 2. $90.00 (7.01% gain) 3. $98.00 (16.67% gain) Target 3 offers a potential ROI of over 17%, aligning with our strategy for significant gains. Monitor RSI closely for signs of reversal or continuation. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:20 AM
$SOLV is currently trading at $85.26, with an RSI of 92.76 indicating it is overbought. The MA30 and MA50 are at 76.05 and 74.54 respectively, suggesting strong bullish momentum. However, the high RSI may signal a potential pullback. The 60D high is $88.2, which could act as resistance, while the low is $66.11, providing a significant range for potential movement. Actionable Trade Alert: - Suggested Entry: $85.50 - Stop Loss: $82.00 (3.0% risk) - Take Profit Targets: 1. $88.00 (3.2% gain) 2. $90.00 (5.8% gain) 3. $100.00 (17.3% gain) Given the current market context, a cautious bullish bias is recommended. Monitor for a potential pullback before entry, and consider taking profits at the outlined targets to secure gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 9:54 PM
$SOLV is currently trading at $85.26, with an RSI of 92.76 indicating it is overbought. The MA30 and MA50 are at 76.05 and 74.54 respectively, suggesting strong bullish momentum. However, the high RSI may signal a potential pullback. The 60D high is $88.2, which could act as resistance, while the low is $66.11, providing a significant range for potential movement. Actionable Trade Alert: - Suggested Entry: $85.50 - Stop Loss: $82.00 (3.0% risk) - Take Profit Targets: 1. $88.00 (3.2% gain) 2. $90.00 (5.8% gain) 3. $100.00 (17.3% gain) Given the current market context, a cautious bullish bias is recommended. Monitor for a potential pullback before entry, and consider taking profits at the outlined targets to secure gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 3 at 3:40 PM
$SOLV Current Stock Price: $85.26 Contracts to trade: $85 SOLV Dec 19 2025 Call Entry: $2.00 Exit: $3.57 ROI: 79% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 11:05 AM
BTIG has adjusted their stance on Solventum ( $SOLV ), setting the rating to Buy with a target price of 100.
0 · Reply
StockBraker
StockBraker Nov. 28 at 2:07 PM
$SOLV Will buy if it dips to $70 or below.
1 · Reply
MACTEP
MACTEP Nov. 27 at 10:28 AM
$SOLV Doomed. Next target - $75
0 · Reply
danaos
danaos Nov. 23 at 11:01 PM
$SOLV Overweight
0 · Reply
ja1234567
ja1234567 Nov. 22 at 3:52 AM
$SOLV quite possibly the stupidest move I have seen in 5 years for any biotech company. Is the a word for overpaid to the point of insanity.
1 · Reply
Boston7452
Boston7452 Nov. 21 at 8:41 PM
$SINT Theres been a scam or really a con going on here but not what youre implying. Tech is game changing and current mgmt is in process of commercializing it. $ZBH $SOLV ?
0 · Reply
prismmarketview
prismmarketview Nov. 21 at 2:40 PM
(NYSE: $SOLV) #solventum is buying #acerasurgical for $850M, adding the fast-growing Restrata synthetic wound-care platform to its portfolio and strengthening its position in the $900M acute regenerative tissue market. https://prismmarketview.com/solventum-expands-advanced-wound-care-portfolio-with-850-million-acquisition-of-acera-surgical/
0 · Reply
topstockalerts
topstockalerts Nov. 20 at 8:54 PM
Solventum Corp shares rose Thursday after announcing a $1 billion share buyback program and the acquisition of Acera Surgical for up to $850 million. The board approved the open-ended buyback, starting in 2026; Solventum had roughly 173.4 million shares outstanding as of October 31, 2025. The acquisition includes $725 million in cash plus up to $125 million in milestone-based payments. Acera, a regenerative wound-care biotech, expands Solventum’s MedSurg portfolio into synthetic tissue matrices, a $900 million U.S. market. Its Restrata products are currently available in the U.S. for complex wound treatment in acute-care settings. CEO Bryan Hanson highlighted that strong financial performance, cash generation, and a healthy balance sheet allow the company to pursue targeted M&A and return capital to shareholders. $SOLV
0 · Reply